Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Post-Market Trading 11-22 17:11:11 EST

1.79

+0.11

+6.55%

盘后1.81

+0.02+1.12%

16:18 EST

High1.79	Low1.60	Vol249.38K
Open1.69	D1 Closing1.68	Amplitude11.31%
Mkt Cap49.24M	Tradable Cap28.58M	Total Shares27.51M
T/O420.23K	T/O Rate1.56%	Tradable Shares15.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":1.79,"timestamp":1732309200000,"preClose":1.68,"halted":0,"volume":249381,"hourTrading":{"tag":"盘后","latestPrice":1.81,"preClose":1.79,"latestTime":"16:18 EST","volume":220,"amount":393.92001,"timestamp":1732310331692},"delay":0,"floatShares":15964753,"shares":27507637,"eps":-0.831087,"marketStatus":"Post-Market Trading","change":0.11,"latestTime":"11-22 17:11:11 EST","open":1.69,"high":1.79,"low":1.6,"amount":420230.705865,"amplitude":0.113095,"askPrice":1.81,"askSize":100,"bidPrice":1.73,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.831087,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732323600000},"marketStatusCode":4,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":1.68,"preHourTrading":{"tag":"盘前","latestPrice":1.74,"preClose":1.68,"latestTime":"08:04 EST","volume":200,"amount":348,"timestamp":1732280684077},"postHourTrading":{"tag":"盘后","latestPrice":1.81,"preClose":1.79,"latestTime":"16:18 EST","volume":220,"amount":393.92001,"timestamp":1732310331692},"volumeRatio":1.157359,"impliedVol":0.5532,"impliedVolPercentile":0.0896},"requestUrl":"/m/hq/s/IMMX/wiki","defaultTab":"wiki","newsList":[{"id":"2483833899","title":"Immix Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483833899","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483833899?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:53","pubTimestamp":1731513231,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc    reported a quarterly adjusted loss of 24 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -23 cents.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2481553152","title":"Immix Biopharma Inc    expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481553152","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481553152?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:14","pubTimestamp":1731014098,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on November 9 (estimated) for the period ending September 30 2024   *    * LSEG's mean analyst est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc    expected to post a loss of 16 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2472696779","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2472696779","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472696779?lang=en_us&edition=fundamental","pubTime":"2024-10-03 19:07","pubTimestamp":1727953620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 03, 2024 07:07 ET (11:07 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2472525348","title":"Immix Biopharma Inc: NOW Dosing at Dose Expansion Level of 450 Mln Nxc-201 Car+T Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2472525348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472525348?lang=en_us&edition=fundamental","pubTime":"2024-10-02 21:32","pubTimestamp":1727875924,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nFWN3LE179:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2472052588","title":"Immix Biopharma Advances CAR-T Nxc-201 to Expansion Cohort Dose Level in U.S. Al Amyloidosis Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2472052588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472052588?lang=en_us&edition=fundamental","pubTime":"2024-10-02 21:32","pubTimestamp":1727875924,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nFWN3LE179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2468572576","title":"Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2468572576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468572576?lang=en_us&edition=fundamental","pubTime":"2024-09-19 21:31","pubTimestamp":1726752660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA3HLM9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2463255739","title":"Immix Biopharma Independent Director Acquires 2.6% More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2463255739","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463255739?lang=en_us&edition=fundamental","pubTime":"2024-08-29 20:49","pubTimestamp":1724935741,"startTime":"0","endTime":"0","summary":"Even if it's not a huge purchase, we think it was good to see that Jason Hsu, the Independent Director of Immix Biopharma, Inc.  recently shelled out US$52k to buy stock, at US$2.23 per share. Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign.In fact, the recent purchase by Independent Director Jason Hsu was not their only acquisition of Immix Biopharma shares this year. They previously made an even bigger purchase of US$267k worth of shares at a price of US$4.88 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price . Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a hi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-independent-director-acquires-124901553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2462648164","title":"Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2462648164","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462648164?lang=en_us&edition=fundamental","pubTime":"2024-08-28 22:30","pubTimestamp":1724855401,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.The newly added locations includ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4572","IE00B19Z6F94.USD","AL","BK4104","IMMX","IE0034390439.USD","BK4139"],"gpt_icon":0},{"id":"2462446377","title":"Immix Biopharma Expands U.S. Clinical Sites for Relapsed/Refractory Al Amyloidosis Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2462446377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462446377?lang=en_us&edition=fundamental","pubTime":"2024-08-28 21:32","pubTimestamp":1724851920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240828:nTUA6K1L2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2460105747","title":"What Makes Immix Biopharma (IMMX) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2460105747","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460105747?lang=en_us&edition=fundamental","pubTime":"2024-08-20 00:00","pubTimestamp":1724083211,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Immix Biopharma, Inc. , as it has been recently upgraded to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.As such, the Zacks rating upgrade for Immix Biopharma is essentially a positive comment on its earnings outlook that could have a favorable impact on ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-immix-biopharma-immx-buy-160011065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2460035906","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2460035906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460035906?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:42","pubTimestamp":1724071320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2024 08:42 ET (12:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2460236081","title":"Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2460236081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460236081?lang=en_us&edition=fundamental","pubTime":"2024-08-19 18:40","pubTimestamp":1724064021,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Equillium (EQ – Research Report), Foghorn Therapeuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-equillium-eq-foghorn-therapeutics-fhtx-and-immix-biopharma-inc-immx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-equillium-eq-foghorn-therapeutics-fhtx-and-immix-biopharma-inc-immx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQ","BK4568","IMMX","BK4139","BK4137","HCSG","FHTX"],"gpt_icon":0},{"id":"2459136285","title":"Immix Biopharma Inc reports results for the quarter ended in June - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2459136285","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459136285?lang=en_us&edition=fundamental","pubTime":"2024-08-14 03:18","pubTimestamp":1723576686,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc    reported a quarterly adjusted loss of 15 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -24 cents.  Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc reports results for the quarter ended in June - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2458523845","title":"Immix Biopharma Inc    expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2458523845","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458523845?lang=en_us&edition=fundamental","pubTime":"2024-08-10 06:56","pubTimestamp":1723244215,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2024   *    * LSEG's mean analyst estimate ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc    expected to post a loss of 21 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2454310379","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2454310379","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2454310379?lang=en_us&edition=fundamental","pubTime":"2024-07-26 19:07","pubTimestamp":1721992020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 26, 2024 07:07 ET (11:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2454883356","title":"California Institute for Regenerative Medicine Awards Funding for CAR-T Nxc-201 U.S. Al Amyloidosis Clinical Trial (Nexicart-2)","url":"https://stock-news.laohu8.com/highlight/detail?id=2454883356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2454883356?lang=en_us&edition=fundamental","pubTime":"2024-07-26 09:31","pubTimestamp":1721957460,"startTime":"0","endTime":"0","summary":"California Institute for Regenerative Medicine Awards Funding for CAR-T Nxc-201 U.S. Al Amyloidosis Clinical Trial (Nexicart-2)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240726:nTUA3MJL4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CAR","BK4230","BK4139","BK4022","IMMX"],"gpt_icon":0},{"id":"2454355624","title":"California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)","url":"https://stock-news.laohu8.com/highlight/detail?id=2454355624","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2454355624?lang=en_us&edition=fundamental","pubTime":"2024-07-26 09:31","pubTimestamp":1721957460,"startTime":"0","endTime":"0","summary":"“AL amyloidosis is an unmet medical need, and current approved therapies for this rare disease are mostly not well tolerated and have not led to sustained remissions,” said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM. “This one-time therapy would be an innovative treatment for patients with AL Amyloidosis, and the preliminary data are encouraging.”About the California Institute for Regenerative Medicine At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today’s most promising stem cell technologies.With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6s.2_eGlVkflCuBx78KjDA--~B/aD0zNzU7dz0xMjExO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/57337275c39e407d905abf969a1a06ad","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6s.2_eGlVkflCuBx78KjDA--~B/aD0zNzU7dz0xMjExO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/57337275c39e407d905abf969a1a06ad"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/california-institute-regenerative-medicine-awards-013100976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","IE0034390439.USD","NXC","BK4183","IE0031619046.USD","BK4104","IE00B66KJ199.SGD","AL","BK4230","BK4022","IE00B19Z6F94.USD","CAR","BK4006","BK4139","BK4572","ODD","IMMX","IE00B7SZL793.SGD","CRS"],"gpt_icon":0},{"id":"2450245017","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2450245017","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450245017?lang=en_us&edition=fundamental","pubTime":"2024-07-09 18:55","pubTimestamp":1720522500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2024 06:55 ET (10:55 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2450080835","title":"Immix Biopharma doses first patient in U.S. AL amyloidosis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2450080835","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450080835?lang=en_us&edition=fundamental","pubTime":"2024-07-09 02:04","pubTimestamp":1720461856,"startTime":"0","endTime":"0","summary":"Immix Biopharma  on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201.The company added that the timing of the milestone was in line with its mid-2024 guidance.It also added that the data from its ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate.Shares of IMMX dropped 7.20% to $2.19 during market hours.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4122687-immix-biopharma-doses-first-patient-in-us-al-amyloidosis-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4104","BK4139","IMMX","IE00B19Z6F94.USD","AL","BK4572"],"gpt_icon":0},{"id":"2449170671","title":"Immix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2449170671","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449170671?lang=en_us&edition=fundamental","pubTime":"2024-07-08 22:15","pubTimestamp":1720448135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4572","IE00B19Z6F94.USD","NXC","IMMX","BK4139","BK4104","AL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.037},{"period":"1month","weight":0.0182},{"period":"3month","weight":-0.2186},{"period":"6month","weight":-0.2533},{"period":"1year","weight":-0.6182},{"period":"ytd","weight":-0.7572}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.057386},{"month":2,"riseRate":0,"avgChangeRate":-0.196349},{"month":3,"riseRate":0,"avgChangeRate":-0.133286},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.121134},{"month":5,"riseRate":0.333333,"avgChangeRate":0.11363},{"month":6,"riseRate":0.666667,"avgChangeRate":0.161675},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.083428},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.078281},{"month":9,"riseRate":0.333333,"avgChangeRate":0.042748},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.044134},{"month":11,"riseRate":1,"avgChangeRate":0.223867},{"month":12,"riseRate":1,"avgChangeRate":0.623385}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction